某种肠道细菌
脂肪肝
脂质代谢
药理学
糖尿病
2型糖尿病
医学
内科学
肠道菌群
内分泌学
化学
生物
生物化学
疾病
作者
Zhaokui Jin,Yuan Sun,Yang Tian,Liwen Tan,Peixun Lv,Qingqing Xu,Geru Tao,Shucun Qin,Xifeng Lu,Qianjun He
出处
期刊:Biomaterials
[Elsevier]
日期:2021-09-01
卷期号:276: 121030-121030
被引量:19
标识
DOI:10.1016/j.biomaterials.2021.121030
摘要
Metabolic dysfunction-associated fatty liver disease (MAFLD) is estimated to affect a quarter of all population and represents a major health threat to all societies. Yet, currently no approved pharmacological treatment is available for MAFLD. H2-rich water has recently been reported to reduce hepatic lipid accumulation in MAFLD patients but its efficacy is limited due to low H2 dosage. Increasing H2 dose may enhance its therapeutic effects but remains technically challenging. In this study, we designed and synthesized a hydrogen nanocapsule by encapsulating ammonia borane into hollow mesoporous silica nanoparticles to achieve ultrahigh and sustained H2 release in the gut. We then investigated its efficacy in treating early-stage MAFLD and other metabolic dysfunctions such as obesity and diabetes. The hydrogen nanocapsule attenuated both diet-induced and genetic mutation induced early-stage MAFLD, obesity, and diabetes in mice, without any tissue toxicity. Mechanistically, we discovered that sustained and ultrahigh H2 supply by hydrogen nanocapsule increased, among other species, the abundance of Akkermansia muciniphila, highlighting reshaped gut microbiota as a potential mechanism of H2 in treating metabolic dysfunctions. Moreover, hepatic transcriptome showed a reprogramed liver metabolism profile with reduced lipid synthesis and increased fatty acid metabolism.
科研通智能强力驱动
Strongly Powered by AbleSci AI